Drug levels, anti-drug antibodies, and clinical efficacy of the anti-TNFα biologics in rheumatic diseases

Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent manner

(2012) Charlotte L Krieckaert et al.   ANNALS OF THE RHEUMATIC DISEASES

Immunogenicity of biological therapeutics

(2012) Charlotte Krieckaert et al.   CURRENT OPINION IN RHEUMATOLOGY

Golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis: results of the GO-FORTH study

(2011) Yoshiya Tanaka et al.   ANNALS OF THE RHEUMATIC DISEASES

Patients non-responding to etanercept obtain lower etanercept concentrations compared with responding patients

(2011) A Jamnitski et al.   ANNALS OF THE RHEUMATIC DISEASES

Venous and arterial thromboembolic events in adalimumab-treated patients with antiadalimumab antibodies: A case series and cohort study

(2011) L. A. Korswagen et al.   ARTHRITIS AND RHEUMATISM

Anti-infliximab antibodies are already detectable in most patients with rheumatoid arthritis halfway through an infusioncycle: an open-label pharmacokinetic cohort study

(2011) Bart JF van den Bemt et al.   BMC MUSCULOSKELETAL DISORDERS

Development of Antidrug Antibodies Against Adalimumab and Association With Disease Activity and Treatment Failure During Long-term Follow-up

(2011) Geertje M. Bartelds   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis

(2011) D. Pascual-Salcedo et al.   RHEUMATOLOGY

Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases

(2011) Emilie Ducourau et al.   ARTHRITIS RESEARCH & THERAPY

The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept

(2010) A. Jamnitski et al.   ANNALS OF THE RHEUMATIC DISEASES

Dealing with immunogenicity of biologicals: assessment and clinical relevance

(2010) Gerrit J Wolbink et al.   CURRENT OPINION IN RHEUMATOLOGY

The effect of immunomodulators on the immunogenicity of TNF-blocking therapeutic monoclonal antibodies: a review

(2010) Charlotte Krieckaert et al.   ARTHRITIS RESEARCH & THERAPY

Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study

(2009) G. M. Bartelds et al.   ANNALS OF THE RHEUMATIC DISEASES

Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis

(2008) T R D J Radstake et al.   ANNALS OF THE RHEUMATIC DISEASES

ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis

(2008) D van der Heijde et al.   ANNALS OF THE RHEUMATIC DISEASES

Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis

(2008) M K de Vries et al.   ANNALS OF THE RHEUMATIC DISEASES

Immunogenicity of anti-tumor necrosis factor antibodies—toward improved methods of anti-antibody measurement

(2008) Lucien Aarden et al.   CURRENT OPINION IN IMMUNOLOGY

Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial

(2008) Paul Emery et al.   LANCET